(Q38005020)

26 August 2017

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus (English)

1 reference

26 August 2017

1 reference

3

Ralph A DeFronzo

1 reference

26 August 2017

Muhammad A Abdul-Ghani

series ordinal

1

1 reference

PubMed ID

22528597

26 August 2017

Luke Norton

series ordinal

2

1 reference

26 August 2017

1 June 2012

1 reference

26 August 2017

Current diabetes report

1 reference

26 August 2017

12

1 reference

26 August 2017

3

1 reference

26 August 2017

230-238

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-012-0275-6

26 August 2017

0 references

cites work

Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs

1 reference

12 December 2020

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

1 reference

12 December 2020

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

12 December 2020

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

1 reference

12 December 2020

Standards of medical care in diabetes--2007.

1 reference

12 December 2020

Is glycemic control improving in U.S. adults?

1 reference

12 December 2020

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

1 reference

12 December 2020

Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats

1 reference

12 December 2020

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

1 reference

12 December 2020

Kidney function in early diabetes: the tubular hypothesis of glomerular filtration

1 reference

12 December 2020

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

1 reference

12 December 2020

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

12 December 2020

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

12 December 2020

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

1 reference

12 December 2020

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

12 December 2020

Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats

1 reference

12 December 2020

1 reference

12 December 2020

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN.

1 reference

12 December 2020

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

1 reference

12 December 2020

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

1 reference

12 December 2020

Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption

1 reference

12 December 2020

Discovery of non-glucoside SGLT2 inhibitors

1 reference

12 December 2020

Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats

1 reference

12 December 2020

Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats

1 reference

12 December 2020

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

1 reference

12 December 2020

1 reference

12 December 2020

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

12 December 2020

Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group

1 reference

12 December 2020

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

12 December 2020

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

1 reference

12 December 2020

10.1007/S11892-012-0275-6

Identifiers

DOI

1 reference

PubMed ID

22528597

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22528597